<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[JJP Biologics 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=45656></link><description><![CDATA[JJP Biologics 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sun, 12 Apr 2026 14:22:22 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2024/05/12_31017998_20240530155132_6144094290.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)]]></title><link>https://www.newswire.co.kr/newsRead.php?no=990699</link><description><![CDATA[WARSAW, Poland--(Business Wire/Korea Newswire)--JJP Biologics, a private biopharmaceutical company developing innovative antibody-based therapies, announces a positive decision, issued by the European Medicines Agency, on the Clinical Trial Application to conduct a phase I clinical study in healthy participants (EudraCT: 2023-508661-33-00) with their potential first-in-class anti-CD89 antagon...]]></description><pubDate>Thu, 30 May 2024 16:45:00 +0900</pubDate></item><item><title><![CDATA[JJP 바이오로직스, 항염증 mAb JJP-1212의 최초 인간 대상 임상시험 수행에 대한 긍정적 결정 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=990701</link><description><![CDATA[바르샤바, 폴란드--(Business Wire/뉴스와이어)--혁신적인 항체 기반 치료제를 개발하는 비공개 바이오 제약 회사인 JJP 바이오로직스(JJP Biologics)가 잠재적인 혁신신약(first-in-class) 항-CD89 길항제인 JJP-1212로 건강한 시험대상자를 대상으로 임상 1상 시험을 수행하기 위한 임상시험신청(EudraCT: 2023-508661-33-00)에 대해 유럽 의약품청(European Medicines Agency)이 발급한 긍정적인 결정을 발표했다.  현재...]]></description><pubDate>Thu, 30 May 2024 16:45:00 +0900</pubDate></item></channel></rss>